中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 37 Issue 12
Dec.  2021
Turn off MathJax
Article Contents
Abstract
References
Supplements
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(12): 2843-2848

Global research hotspots and trends in the field of immunotherapy for liver cancer in 2011-2020 based on CiteSpace analysis

DOI: 10.3969/j.issn.1001-5256.2021.12.022
  • 1.

    Key Laboratory, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China

  • 2a.

    State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

  • 2b.

    Office of Academic Research, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

  • 3.

    Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China

Research funding:

National Natural Science Foundation of China (81773170)

  • Received Date: 2021-05-10
  • Accepted Date: 2021-06-15
  • Published Date: 2021-12-20
    Abstract
  •   Objective  To investigate the research hotspots and trends in the field of immunotherapy for liver cancer in 2011-2020 based on bibliometric methods.  Methods  The Web of Science-SCI Expanded database was searched with the following search strategy: #1 TS = (Liver Neoplasms OR Neoplasms, Hepatic OR Neoplasms, Liver OR Liver Neoplasm OR Neoplasm, Liver OR Hepatic Neoplasms OR Hepatic Neoplasm OR Neoplasm, Hepatic OR Cancer of Liver OR Hepatocellular Cancer OR Cancers, Hepatocellular OR Hepatocellular Cancers OR Hepatic Cancer OR Cancer, Hepatic OR Cancers, Hepatic OR Hepatic Cancers OR Liver Cancer OR Cancer, Liver OR Cancers, Liver OR Liver Cancers OR Cancer of the Liver OR Cancer, Hepatocellular) AND #2 TS = (Immunotherapy OR Immunotherapies OR Immunity therapy); time span: 2011-2020; type of literature: Article; language: English. CiteSpace software was used to perform a visualized analysis of the articles in the field of immunotherapy for liver cancer published in 2011-2020 from the aspects of the distributions of year, country, institution, author, journal, and fund, times cited, and keywords, and the frequency, centrality, and clustering of keywords were discussed.  Results  A total of 1972 articles on immunotherapy for liver cancer were included, and the analysis showed that China was the country with the largest number of articles, Sun Yat-sen University was the institution with the largest number of articles, and Journal for Immunotherapy of Cancer was the journal with the largest number of articles. The research hotspots in this field included tumor-associated macrophages, oncolytic virus (such as adenovirus), tumor vaccine therapy, adoptive cellular immunotherapy, immune checkpoint inhibitors, and combined immunotherapy. The trend of this field was tumor vaccine therapy → immunotherapy for oncolytic virus → adoptive cellular immunotherapy → immune checkpoint inhibitor therapy.  Conclusion  Immunotherapy for liver cancer has undergone continuous development in the recent ten years, and with the research and development of tumor vaccine therapy, oncolytic virus, and immune checkpoint inhibitors and the improvement of immune checkpoint inhibitors, combined treatment based on immunotherapy is expected to further improve the clinical outcome of liver cancer.

     

    • FullText(HTML)
    • References(15)
  • [1]
    SUN KX, ZHENG RS, ZHANG SW, et al. Report of cancer incidence and mortality in different areas of China, 2015[J]. China Cancer, 2019, 28(1): 1-11. DOI: 10.11735/j.issn.1004-0242.2019.01.A001.

    孙可欣, 郑荣寿, 张思维, 等. 2015年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2019, 28(1): 1-11. DOI: 10.11735/j.issn.1004-0242.2019.01.A001.
    [2]
    YUAN SX, ZHOU WP. Progress and hot spots of comprehensive treatment for primary liver cancer[J]. Chin J Dig Surg, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776.

    袁声贤, 周伟平. 原发性肝癌综合治疗的进展和热点[J]. 中华消化外科杂志, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776.
    [3]
    HOLLEBECQUE A, MALKA D, FERTÉ C, et al. Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons[J]. Eur J Cancer, 2015, 51(3): 327-339. DOI: 10.1016/j.ejca.2014.12.005.
    [4]
    LIANG J, LI L. Progress and consideration of immunotherapy strategy for hepatocellular carcinoma[J]. Chin J Dig Surg, 2021, 20(2): 184-190. DOI: 10.3760/cma.j.cn115610-20201228-00809.

    梁军, 李丽. 肝癌免疫治疗策略的进展与思考[J]. 中华消化外科杂志, 2021, 20(2): 184-190. DOI: 10.3760/cma.j.cn115610-20201228-00809.
    [5]
    YAO L, HUI L, YANG Z, et al. Freshwater microplastics pollution: Detecting and visualizing emerging trends based on Citespace Ⅱ[J]. Chemosphere, 2020, 245: 125627. DOI: 10.1016/j.chemosphere.2019.125627.
    [6]
    MURRAY AG, WARDEH M, MCINTYRE KM. Using the H-index to assess disease priorities for salmon aquaculture[J]. Prev Vet Med, 2016, 126: 199-207. DOI: 10.1016/j.prevetmed.2016.02.007.
    [7]
    EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
    [8]
    NAKAMOTO Y, MIZUKOSHI E, KITAHARA M, et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization[J]. Clin Exp Immunol, 2011, 163(2): 165-177. DOI: 10.1111/j.1365-2249.2010.04246.x.
    [9]
    HUANG H, LIU Y, LIAO W, et al. Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy[J]. Nat Commun, 2019, 10(1): 4801. DOI: 10.1038/s41467-019-12794-2.
    [10]
    ROSEWELL SHAW A, SUZUKI M. Oncolytic viruses partner with T-cell therapy for solid tumor treatment[J]. Front Immunol, 2018, 9: 2103. DOI: 10.3389/fimmu.2018.02103.
    [11]
    WANG Y, YANG X, YU Y, et al. Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells[J]. J Cancer, 2018, 9(2): 275-287. DOI: 10.7150/jca.22176.
    [12]
    KOJIMA Y, VOLKMER JP, MCKENNA K, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis[J]. Nature, 2016, 536(7614): 86-90. DOI: 10.1038/nature18935.
    [13]
    BARKAL AA, WEISKOPF K, KAO KS, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy[J]. Nat Immunol, 2018, 19(1): 76-84. DOI: 10.1038/s41590-017-0004-z.
    [14]
    SANGRO B, GOMEZ-MARTIN C, de la MATA M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol, 2013, 59(1): 81-88. DOI: 10.1016/j.jhep.2013.02.022.
    [15]
    LEE MS, RYOO BY, HSU CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma(GO30140): Anopen-label, multicentre, phase 1b study[J]. Lancet Oncol, 2020, 21(6): 808-820. DOI: 10.1056/NEJMoa1915745.
    • Relative Articles

  • Relative Articles

    [1]Weiming DAI, Lungen LU, Xiaobo CAI. Association between liver sinusoidal endothelial cells and liver fibrosis[J]. Journal of Clinical Hepatology, 2023, 39(2): 419-423. doi: 10.3969/j.issn.1001-5256.2023.02.027
    [2]Yu ZHANG, Huali WANG, Shuming LU. Three cases of hepatic epithelioid hemangioendothelioma[J]. Journal of Clinical Hepatology, 2022, 38(9): 2116-2119. doi: 10.3969/j.issn.1001-5256.2022.09.031
    [3]Hao XU, Bai RUAN, Zhiwen LI, Zhiqiang FANG, Lin WANG, Kefeng DOU. Establishment of a mouse model of vascular endothelial-mesenchymal transdifferentiation genetic tracing and its role in liver fibrosis studies[J]. Journal of Clinical Hepatology, 2022, 38(4): 832-836. doi: 10.3969/j.issn.1001-5256.2022.04.018
    [4]Jin XU, Yan PENG, Chuankang TANG. Value of neutrophil-lymphocyte ratio combined with apolipoprotein A-I level in predicting the severity of acute pancreatitis in the early stage after admission[J]. Journal of Clinical Hepatology, 2021, 37(3): 660-665. doi: 10.3969/j.issn.1001-5256.2021.03.030
    [5]Wei BiWei, Gong YaHui, Liang ZhiHai. Role of pyroptosis in the pathogenesis of acute pancreatitis[J]. Journal of Clinical Hepatology, 2020, 36(8): 1905-1908. doi: 10.3969/j.issn.1001-5256.2020.08.050
    [6]Qi QinQin, Yang Bin, Li HuiHui, Bao JunJun, Li HongYe, Wang BingBing, Mei Qiao. Level of platelet microparticles in acute pancreatitis and their role in the formation of neutrophil extracellular traps[J]. Journal of Clinical Hepatology, 2020, 36(4): 870-873. doi: 10.3969/j.issn.1001-5256.2020.04.032
    [7]Jiang Zhao, Ruan Bo. The role of liver sinusoidal endothelial cells in the progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(3): 684-686. doi: 10.3969/j.issn.1001-5256.2020.03.047
    [8]Zhu ZiYi, Liu Yuan, Wang WenBo, Jiang ZhongYong, Chang Kai, Ye YuSheng, Xiong Jie. Mechanism of HCV stimulation of human umbilical vein endothelial cells in the pathogenesis of atherosclerosis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1313-1317. doi: 10.3969/j.issn.1001-5256.2019.06.026
    [9]Yu ZiYue, Lin Xin, Han Ying, Cui LiNa. Role of liver sinusoidal endothelial cells in liver regeneration and the development of liver fibrosis[J]. Journal of Clinical Hepatology, 2019, 35(9): 2072-2074. doi: 10.3969/j.issn.1001-5256.2019.09.041
    [10]Wang Lin, Liu XueEn, Zhuang Hui. Cellular mechanisms in liver fibrosis regression[J]. Journal of Clinical Hepatology, 2018, 34(4): 862-866. doi: 10.3969/j.issn.1001-5256.2018.04.036
    [11]Zhu ZeMin, Xie ZhiQin, Zhao ZhiJian, Li HongXia, Xu Tao, Tang CaiXi. Pancreatic acinar cell carcinoma with acute pancreatitis as the first symptom: A case report[J]. Journal of Clinical Hepatology, 2018, 34(12): 2662-2664. doi: 10.3969/j.issn.1001-5256.2018.12.032
    [12]Hu QingMei, Niu ChunYan. Predictive value of combined measurement of D-dimer, fibrinogen, and peripheral blood leukocyte count for severity of acute pancreatitis[J]. Journal of Clinical Hepatology, 2017, 33(8): 1522-1526. doi: 10.3969/j.issn.1001-5256.2017.08.023
    [13]Wang Yan, Cui LiJian, Xiao HongLi, Wang GuoXing, Yin ChengHong. Effect of angiotensin 1-7 on the TLR4/NF-κB pathway in cerulein-induced pancreatic acinar cells[J]. Journal of Clinical Hepatology, 2016, 32(11): 2146-2150. doi: 10.3969/j.issn.1001-5256.2016.11.029
    [14]Jiao ShuHua, Liu PengLiang, Wen YanHui. Combined determination of serum C-reactive protein,lipase,interleukin-1β,and intercellular adhesion molecule1 in early identification of severity of acute pancreatitis[J]. Journal of Clinical Hepatology, 2016, 32(1): 131-134. doi: 10.3969/j.issn.1001-5256.2016.01.025
    [15]Hao TingTing, Ma XiaoPeng, Wen YanLi, Dai GuangRong, Feng YiChao, Zhang Li. Changes in serum levels of M30,M65,and IL-17 and their clinical significance in patients with acute pancreatitis[J]. Journal of Clinical Hepatology, 2016, 32(2): 329-332. doi: 10.3969/j.issn.1001-5256.2016.02.027
    [16]Lu Wang, Zhang Rui, Jiang HongLi, Hu YuLin, Xin GuiJie. One case of hepatic epithelioid hemangioendothelioma[J]. Journal of Clinical Hepatology, 2015, 31(8): 1330-1331. doi: 10.3969/j.issn.1001-5256.2015.08.038
    [17]Wu Gang, Zheng Jie, Hu GuoXin, Peng YanZhong. Role of liver nonparenchymal cells in hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2014, 30(12): 1366-1369. doi: 10.3969/j.issn.1001-5256.2014.12.033
    [18]Ren LiNan, Guo XiaoZhong, Zou DeLi. EG-VEGF expression and significance in pancreatic carcinoma[J]. Journal of Clinical Hepatology, 2012, 28(8): 589-591.
    • Supplements(1)
  • 12期单独排.pdf
    • Cited By

  • Cited by

    Periodical cited type(15)

    1. 许娟，闫涛涛，李严锋，侯静涛，樊研. ALBI评分联合PCT在肝硬化腹水患者自发性细菌性腹膜炎的预测作用. 胃肠病学和肝病学杂志. 2023(01): 85-89 .
    2. 周苏云，周影，程新月. 肝硬化患者发生肝性脑病的影响因素分析及对预检分诊意义的探讨. 中西医结合护理(中英文). 2023(03): 130-132 .
    3. 方翊天，吴若林，黄帆，王国斌，冯丽娟，余孝俊，侯刘进，叶征辉，耿小平，赵红川. 肝移植术后多重耐药菌感染危险因素的单中心临床研究. 器官移植. 2021(02): 197-202 .
    4. 李尚书，刘群，黄丽雯. 慢性肝病血小板减少的原因. 中国肝脏病杂志(电子版). 2021(02): 24-28 .
    5. 陆素芳，周红，王丹丹，陈益群，赵红利，张勇杨. MELD评分联合SII对失代偿期肝硬化患者预后的预测作用. 现代消化及介入诊疗. 2021(08): 973-977 .
    6. 黄敏，李冬冬，刘传苗. 乙肝相关慢加急性肝衰竭患者临床短期预后因素的分析. 中华全科医学. 2021(12): 2028-2030 .
    7. 贾亚男，李瀚，李先亮，贺强. 危重症肝病肝移植患者诊断和评估标准的临床进展. 器官移植. 2020(03): 326-331+368 .
    8. 姚运海，赵卫峰，甘建和. 苏州地区血吸虫性肝病患者临床特征及外周血T淋巴细胞亚群分布. 中国血吸虫病防治杂志. 2020(02): 154-158+167 .
    9. 张耀弟. △CTP评分评估肝硬化患者短期预后的价值分析. 甘肃科技. 2020(09): 117-118+152 .
    10. 刘小婷，杨欢，姚红，任小婵，罗选娟，王小闯. 碳青霉烯类耐药肺炎克雷伯菌感染死亡风险预测模型的建立及其对患者预后的预测价值研究. 中国全科医学. 2020(30): 3789-3797 .
    11. 韩志钧，韩柠泽，闫伟，马金彤. 肝血流动力学变化与肝储备功能相关性的研究. 中华医学超声杂志(电子版). 2020(06): 563-565 .
    12. 寇建涛，刘喆，朱继巧，马军，许文犁，李瀚，贾亚男，李先亮，贺强. 肝移植治疗危重症肝病的临床疗效研究. 器官移植. 2020(04): 482-486 .
    13. 宋梅，汪明星，李乐，何进伟，何丽丽. MELD评分结合降钙素原评估终末期肝病预后的临床分析. 中国医药科学. 2020(09): 254-256 .
    14. 李帆，成金英，刘贤贤，丁国锋. 乙肝肝硬化并发甲型流感及肺曲霉菌病1例并文献复习. 中国当代医药. 2020(34): 214-217 .
    15. 韩志钧，韩柠泽，闫伟，马金彤. 肝血流动力学变化与吲哚菁绿代谢试验评价肝储备功能的对比. 医学研究与教育. 2019(06): 28-31 .

    Other cited types(1)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 24.8 %FULLTEXT: 24.8 %META: 69.6 %META: 69.6 %PDF: 5.5 %PDF: 5.5 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 8.3 %其他: 8.3 %其他: 1.6 %其他: 1.6 %China: 0.8 %China: 0.8 %Russian Federation: 0.3 %Russian Federation: 0.3 %[]: 0.5 %[]: 0.5 %三亚: 0.2 %三亚: 0.2 %上海: 1.8 %上海: 1.8 %中卫: 0.2 %中卫: 0.2 %佛山: 0.2 %佛山: 0.2 %兰州: 0.3 %兰州: 0.3 %北京: 4.4 %北京: 4.4 %南京: 1.3 %南京: 1.3 %南宁: 0.3 %南宁: 0.3 %南阳: 0.2 %南阳: 0.2 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %台州: 0.2 %台州: 0.2 %合肥: 1.5 %合肥: 1.5 %吉林: 0.5 %吉林: 0.5 %呼和浩特: 0.3 %呼和浩特: 0.3 %唐山: 0.2 %唐山: 0.2 %商丘: 0.2 %商丘: 0.2 %大连: 0.2 %大连: 0.2 %天津: 0.2 %天津: 0.2 %太原: 0.2 %太原: 0.2 %宁波: 0.2 %宁波: 0.2 %安康: 0.2 %安康: 0.2 %安阳: 0.2 %安阳: 0.2 %宣城: 0.3 %宣城: 0.3 %密蘇里城: 1.1 %密蘇里城: 1.1 %巴黎: 0.5 %巴黎: 0.5 %常德: 0.2 %常德: 0.2 %广州: 0.3 %广州: 0.3 %张家口: 4.4 %张家口: 4.4 %德罕: 0.2 %德罕: 0.2 %成都: 0.5 %成都: 0.5 %扬州: 0.2 %扬州: 0.2 %拉斯维加斯: 0.5 %拉斯维加斯: 0.5 %昆明: 0.2 %昆明: 0.2 %杭州: 0.2 %杭州: 0.2 %武汉: 1.1 %武汉: 1.1 %洛阳: 0.3 %洛阳: 0.3 %济南: 0.2 %济南: 0.2 %海得拉巴: 0.5 %海得拉巴: 0.5 %湖州: 0.2 %湖州: 0.2 %湘潭: 0.2 %湘潭: 0.2 %湛江: 0.2 %湛江: 0.2 %漯河: 0.2 %漯河: 0.2 %福州: 0.2 %福州: 0.2 %罗奥尔凯埃: 0.2 %罗奥尔凯埃: 0.2 %自贡: 0.2 %自贡: 0.2 %芒廷维尤: 43.0 %芒廷维尤: 43.0 %芝加哥: 0.5 %芝加哥: 0.5 %苏州: 0.2 %苏州: 0.2 %茂名: 0.2 %茂名: 0.2 %莫斯科: 3.6 %莫斯科: 3.6 %西宁: 10.4 %西宁: 10.4 %诺沃克: 0.6 %诺沃克: 0.6 %贵阳: 0.2 %贵阳: 0.2 %运城: 2.3 %运城: 2.3 %金华: 0.3 %金华: 0.3 %长春: 1.8 %长春: 1.8 %长沙: 0.5 %长沙: 0.5 %长治: 0.2 %长治: 0.2 %马湾: 0.2 %马湾: 0.2 %马鞍山: 0.2 %马鞍山: 0.2 %黔西南: 0.2 %黔西南: 0.2 %其他其他ChinaRussian Federation[]三亚上海中卫佛山兰州北京南京南宁南阳卡纳塔克台州合肥吉林呼和浩特唐山商丘大连天津太原宁波安康安阳宣城密蘇里城巴黎常德广州张家口德罕成都扬州拉斯维加斯昆明杭州武汉洛阳济南海得拉巴湖州湘潭湛江漯河福州罗奥尔凯埃自贡芒廷维尤芝加哥苏州茂名莫斯科西宁诺沃克贵阳运城金华长春长沙长治马湾马鞍山黔西南

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (543) PDF downloads(48) Cited by(16)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[3692]YesterdayPV[7162]TodayIP[4992]TodayPV[10586]Online[251]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return